# A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970

> **NCT04106297** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 100 (actual)

## Conditions studied

- Healthy
- Psoriasis

## Interventions

- **DRUG:** GLPG3970 oral solution
- **DRUG:** Placebo oral solution
- **DRUG:** GLPG3970 capsule

## Key facts

- **NCT ID:** NCT04106297
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-10
- **Primary completion:** 2021-03-05
- **Final completion:** 2021-03-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04106297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04106297, "A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04106297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*